A case of dose-dependent aripiprazole-induced conduction disturbance [4]

Journal of Clinical Psychopharmacology

Volumn 26, Issue 4, 2006, Pages 436-

  Egger, Cristoph ^a   Rauscher, Alexander ^a   Muehlbacher, Moritz ^a   Nickel, Marius ^a,b   Geretsegger, Christian ^a   Stuppaeck, Christoph ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b Clinic for Psychosomatic Medicine   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL; LAMOTRIGINE; LORAZEPAM; QUETIAPINE;

ADULT; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CASE REPORT; ELECTROCARDIOGRAPHY; EXPERIENCE; FEMALE; HEART MUSCLE CONDUCTION DISTURBANCE; HEART REPOLARIZATION; HUMAN; LETTER; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT;

ADULT; ANTIPSYCHOTIC AGENTS; BUNDLE-BRANCH BLOCK; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA;

EID: 33746916399     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000231267.94210.e5     Document Type: Letter

References (3)

1. Ames D, Camm J, Cook P, et al. Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group. Encephale. 2002;28(6 Pt 1): 552-562.
2. Fleischhacker WW. Aripiprazole. Expert Opin Pharmacother. 2005;6(12):2091-2101.
3. Hirose T, Uwahodo Y, Yamada S, et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol. 2004;18(3):375-383.